Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Polio vaccine bites back

15.03.2002


Weakened polio borrows genes to gain strength for outbreak

Genetic sleuthing has revealed how a dose of oral polio vaccine (OPV) can revert to the deadly poliovirus and cause an outbreak. The research highlights problems that global health organizations face completing their eradication of polio, and the urgency of that effort1.

"It reminds us that we need to be very careful in our development of a post-eradication policy," says Bruce Aylward, leader of the World Health Organization’s polio eradication program.



Since the 1960s the use of OPV, a weakened form of the deadly poliovirus, has nearly eradicated the paralytic disease poliomyelitis worldwide. In 2000 there were just 2000 cases.

That OPV can revert to a more virulent form has been known since its creation. But it has only recently become a problem — widespread eradication means that susceptibility to poliovirus is on the rise.

The new research is yet another illustration of how the vaccine has fallen victim to its own success.

No wall of immunity

The Americas were declared free of wild poliovirus in 1999. Around this time a polio outbreak began on Hispaniola, a Caribbean island shared by the Dominican Republic and Haiti. The disease killed two children and paralysed a further 19.

From the genetic sequence of virus samples from each of these children, virologist Olen Kew at the US Centers for Disease Control and Prevention in Atlanta, Georgia, and his team have now deduced the origin of the deadly virus. "It came from a single dose of OPV given to a single [probably Haitian] child," says Kew.

Genes crucial to polio’s virulence are switched off in OPV. They had switched back on in the Hispaniola virus, the researchers found, probably through random mutation. This is hardly surprising because poliovirus "is one of the most rapidly evolving viruses we know", says Kew.

The researchers found other genes that didn’t belong to polio at all. The offending virus had borrowed genetic information from related gut pathogens called enteroviruses in the children it infected. This cut’n’paste trick may have enabled it to regain strength more quickly than it could by random mutation. "It is a great shortcut," says Mark Pallanch, a member of the CDC team.

Fortunately this kind of reversion can only happen in certain situations, says Pallanch. The situation in Hispaniola, it turns out, was perfect.

As many as 20% of children in some parts of Hispaniola had not been fully vaccinated with OPV. And wild poliovirus, which also causes immunity, had been absent from the island for many years. So there were sufficient children on the island who were susceptible enough to polio to carry and spread the virus

In Hispaniola "the process of reversion was not blocked by a wall of immunity", says Kew. OPV passed from child to child, replicating as it went. It reverted to a virulent form in about a year, the researchers estimate.

Time running out

Good vaccine coverage in most areas means that such outbreaks are rare. But two others recently in Egypt2 and the Philippines3 have raised concerns that the clock is ticking on efforts to eradicate polio globally4.

The big fear is a vaccine-derived outbreak devastating a completely susceptible child population, in the United States or Europe, which have been free of polio and OPV for decades, for instance.

To prevent this, OPV must be given to children in unvaccinated areas as quickly as possible and in a synchronized manner. The vaccine must then be withdrawn from use immediately. "The ongoing use of OPV poses a risk in itself," says Kew.

"It confirms something we already knew," says Aylward, who is concentrating on plans to phase out OPV. The recent OPV-related outbreaks have provided an idea of what to watch out for, he says. "We’ve now heightened our surveillance worldwide to catch this," he adds.

References

  1. Kew, O.et al.Hispaniola associated with circulating type 1 vaccine derived poliovirus. Science, Published online, March 14 (2002).
  2. Circulation of a type-2 vaccine-derived poliovirus — Egypt, 1982–1993. CDC Morbidity and Mortality Weekly Report, 50, 41–42, (2001).
  3. Public health dispatch: Acute flaccid paralysis associated with circulating vaccine-derived poliovirus — Philippines, 2001. CDC Morbidity and Mortality Weekly Report, 50, 874–875, (2001).
  4. Clarke, T. Polio’s last stand. Nature, 409, 278– - 280, (2001).

    TOM CLARKE | Nature

More articles from Health and Medicine:

nachricht Fast-tracking T cell therapies with immune-mimicking biomaterials
16.01.2018 | Wyss Institute for Biologically Inspired Engineering at Harvard

nachricht Dengue takes low and slow approach to replication
12.01.2018 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Novel 3-D printing technique yields high-performance composites

16.01.2018 | Materials Sciences

New application for acoustics helps estimate marine life populations

16.01.2018 | Life Sciences

Fast-tracking T cell therapies with immune-mimicking biomaterials

16.01.2018 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>